KAIROS PHARMA LTD (KAPA)
AMEXHealth CareBiotechnologySnapshot 2026-11-04
$0.49-3.03%
Close 2026-11-04 · 1-day change
AMEXHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · KAPA
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
KAPA — capital allocation
Dated 2026-08-21
of Form 8-K, the information regarding the Reverse Stock Split (as defined below) contained in
Why it matters: The Bayer work is an early research effort. A clear next step would show progress, while a stopped effort would weaken this path.
Watch forKairos or Bayer reports a named next research step for combining ENV-105 with radium, such as a study start.
Also watch forKairos or Bayer reports that the ENV-105 and radium research has ended or been paused.
Why it matters: A trial start would show progress on Kairos's lung cancer program. No clinical results for CL-741 are reported yet.
Supportive ifKairos announces that the CL-741 Phase 1 study has started by December 31, 2026.
Worry ifKairos reports that the CL-741 Phase 1 study has not started by December 31, 2026, or delays its start.
Why it matters: Kairos is losing money, and recent losses have grown. The report can show whether that trend continues.
Worry ifThe November 13 report shows a net loss greater than $1.65 million for the quarter.
Less concerning ifThe November 13 report shows a net loss below $1.65 million for the quarter.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$388 on $10,000 · ±3.9% | How much price usually moves either way. |
| Bad day | $973 loss on $10,000 · 9.7% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,302 loss on $10,000 · 93.0% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.